This is a study of CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin. Patients are assigned to receive 4 circles of cell therapy. The safety and clinical response are evaluated. Biomarkers and immunological markers are also monitored.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically verified stage IV gastric carcinoma, nasopharyngeal carcinoma and lymphoma with measurable lesions (At least one measurable lesion or the immunotherapy)
Pathologically verified as EBV positive malignancies
Human leukocyte antigen (HLA) genotypes: HLA-A02, HLA-A24 or HLA-A11 genotypes
Progressed after standard treatment or the patients refused to accept the standard treatment
Performance score: 0-1
Expected life span: \>= 3 months
Toxicities from prior treatment has resolved. Washout period is 1 months
Major organs function normally
Women at pregnant ages should be under contraception
Willing and able to provide informed consent
You may not be if
Patients with possible drug allergy of immunotherapy
Patients with active bacterial or fungal infections
Coagulopathy, or ongoing thrombolytics and/or anticoagulation
Blood-borne infectious disease, e.g. hepatitis B, hepatitis C and HIV
History of coronary artery disease, asthma, or vascular disease or other disease inappropriate for treatment deemed by treating physician
With other tumors except for in situ cervical cancer, treated squamous cell carcinoma and bladder cancer (Ta and TIS) or other malignancies that have been treated with radical therapy (at least for 5 years before the enrollment)
With other immune diseases, or chronic use of immunosuppressants or steroids
Pregnant and lactating women
Compliance cannot be expected
Other conditions requiring exclusion deemed by physician
Clareo Health | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
